Details of Drug-Drug Interaction
| Drug General Information (ID: DDIJHWCIYQ) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Drug Name | Iron | Drug Info | Dolutegravir | Drug Info | |||||
| Drug Type | Small molecule | Small molecule | |||||||
| Therapeutic Class | Iron Supplement | Antiviral Agents | |||||||
| Structure | |||||||||
| Mechanism of Iron-Dolutegravir Interaction (Severity Level: Major) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Complex formation Click to Show/Hide Mechanism Graph | |||||||||
![]() |
|||||||||
| Drug Name | Iron | Dolutegravir | |||||||
| Mechanism | Polyvalent cations | Binds to polyvalent cations | |||||||
| Key Mechanism Factor 1 | |||||||||
| Factor Name | Chelation | ||||||||
| Factor Description | Chelation is a direct drug interaction that usually involves the formation of dimers or trimers, resulting in larger complexes and poorer absorption. | ||||||||
| Mechanism Description |
|
||||||||
| Recommended Action | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Management | Dolutegravir should be administered 2 hours before or 6 hours after medications containing polyvalent cations such as antacids, laxatives, or mineral supplements. | ||||||||

